Oving, I.M.

mw. dr. I.M. Oving

Afspraak maken?

Aandachtsgebieden

  • Interne geneeskunde
  • Oncologie

BIG-nummer

89041100101

Wetenschappelijke publicaties en onderzoeken

  • Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment

    Boerrigter E, Benoist GE, Oort IM van , Verhaegh GW, Hooij O van , Groen L, Smit F, Oving IM, Mol P de, Smilde TJ.
    Mol Oncol 2021; :doi: 10.1002/1878-0261.12933. Online ahead of print..

  • Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.

    Ramshorst MS van , Voort A van der , Werkhoven ED van , Mandjes IA, Kemper I, Dezentjé VO, Oving IM.
    Lancet Oncol. 2018; 19(12):1630-1640.

    Publicatie openen
  • Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study

    Ramshorst MS van, Werkhoven E van, Honkoop AH, Dezentjé VO, Oving IM, Mandjes IA, Kemper I, Smorenburg CH, Stouthard JM, Linn SC, Sonke GS.
    Breast 2016 Epub 2016; 5:doi: 10.1016/j.breast.2016.07.017. .

    Publicatie openen
  • Safety analyses of the first 110 patients treated with dual HER2-blockade in the TRAIN-2 study

    Ramshorst M van, Werkhoven E van, Honkoop A, Dezentje V, Oving IM, Mandjes I.
    Eur J Cancer 2016; 57:S96:Suppl 2.